Artificial Intelligence
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) — Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-009-01 and myCare-009-02 clinical studies in which Cellworks Singula™ performed as a superior predictor of complete response (CR) to therapies for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) cancer patients compared to physician prescribed treatments (McNemar’s p < 0.00001).
Cellworks Singula™ correctly predicted 88.5% of AML responders and non-responders with 97.0% sensitivity and 68.0% specificity, compared to a 70.2% physician prescribed treatment response rate in the myCare-009-01 study. Cellworks Singula™ also correctly predicted 73.3% of MDS responders and non-responders with 97.0% sensitivity and 68.0% specificity, compared to a 37.7% physician prescribed treatment response rate in the myCare-009-02 study. Cellworks Singula™ was a significant predictor of overall survival (p-value < 0.0001) and provided predictive information above and beyond physician prescribed treatments in both studies.The complete results from the myCare-009-01 and myCare-009-02 clinical studies are now available in the ASCO Meeting Library as abstracts e19502 and e19528, respectively.“These studies validate that Cellworks Singula™ is a leap forward for Personalized Medicine,” said Dr. Guido Marcucci, MD, Chair and Professor, Department of Hematologic Malignancies Translational Science, Director, Gehr; Family Center for Leukemia Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; and Primary Investigator for the myCare-009-01 and myCare-009-02 clinical studies. “Most AML and MDS patients have not just one, but multiple molecular aberrations, each of which impacts how individual patients respond to treatments. Cellworks Singula™ is a breakthrough technology that biosimulates how individual AML and MDS patients with multiple aberrations respond to specific therapies and then produces personalized therapy response predictions with very high accuracy. This novel capability has the potential to increase AML and MDS therapy response rates and improve patient outcomes.”The current overall outcomes for AML and MDS patients remain relatively poor. Physicians select therapies for patients based on information that only considers cytogenetics and single molecular aberrations and ignores other potentially impactful molecular pathways, downstream effects and patient-specific ’omics data that have the potential to inform more effective treatments.“Cellworks biosimulation is an exciting technology that delivers Personalized Medicine to AML and MDS patients,” said Dr. Anthony Stein, MD, Hematologist/Oncologist, Director of the Leukemia Program; Co-Director of the Gehr Family Center for Leukemia Research; Clinical Professor of Hematology & Hematopoietic Transplantation at City of Hope; and Primary Investigator for the myCare-009-01 and myCare-009-02 clinical studies. “These studies show that Cellworks Singula™ can accurately predict how an individual AML or MDS patient will respond to specific therapies. These precise, data-driven predictions can enable physicians to avoid prescribing inefficacious treatments and can empower physicians to make more efficacious therapy decisions based on their patient’s unique molecular biology.”Cellworks Singula™ therapy response predictions are generated through extensive biosimulation of a personalized patient disease model based on the patient’s multi-omics data. Utilizing an in-silico model of thousands of genes, Cellworks Singula™ analyzes the downstream pathway impact of genomic, proteomic, transcriptomic and epigenomic aberration information on a patient’s disease. These downstream effects generate phenotypic impact, which are calculated against specific drugs or drug combinations to determine treatment efficacy. The Cellworks biosimulation platform can predict an individual patient’s therapy response prior to receiving the treatment, thereby reducing the patient risks and payer costs of unsuccessful treatments and saving lives.myCare-009-01 Clinical StudyAn independent cohort of 494 AML patients, 2 to 85 years in age (median age 54) and treated with physician prescribed therapy, were randomly selected for this prospective retrospective study. Patient ’omics data from PubMed was used for the study. The accuracy of Cellworks Singula™ therapy response predictions was compared to the accuracy of prescribed therapies and clinical outcomes. Accuracy comparisons were enabled using McNemar’s test to account for the correlation between Cellworks Singula™ and physician recommendations. Logistic regression was used to model complete response (CR) as a function of age, prescribed therapies and Cellworks Singula™ against non-response (NR). Similar analyses were performed for overall survival (OS) using proportional hazards regression.Study results show that Cellworks Singula™ is a superior predictor for complete response (CR) in AML patients (McNemar’s χ2 = 72.0, p < 0.0001) with an overall predictive accuracy of 88.5% (Exact 95% CI: 85.3%, 91.1%) relative to physician prescribed treatments, compared to a physician prescribed treatment response rate of 70.2% (95% CI: 66.0%, 74.2%). Cellworks Singula™ exhibited 97.1% sensitivity (95% CI: 94.8%, 98.6%) and 68.0% specificity (95% CI: 59.8%, 75.5%). Cellworks Singula™ was also an independent predictor for OS (HR = 2.080, p < 0.0001) after adjusting for patient age (p = 0.0018) and physician prescribed treatment (p = 0.0011). For all 100 true negatives, Cellworks Singula™ generated alternative standard of care therapy selections with predicted clinical response.myCare-009-02 Clinical StudyAn independent cohort of 146 MDS patients aged 28 to 89 years (median age 69) and treated with physician prescribed therapy were randomly selected for this prospective retrospective study. Patient ’omics data from PubMed and The Cancer Genome Atlas (TCGA) was used for the study. The accuracy of Cellworks Singula™ therapy response predictions was compared to the accuracy of prescribed therapies and clinical outcomes. Accuracy comparisons were enabled using McNemar’s test to account for the correlation between Cellworks Singula™ and physician recommendations. Multivariate logistic regression modeled complete response (CR) as a function of patient age, physician prescribed treatment and Cellworks Singula™ against non-response (NR).Study results show Cellworks Singula™ is a superior predictor for complete response (CR) in MDS patients (McNemar’s χ2 = 42.0, p < 0.0001) with an overall predictive accuracy of 73.3% (Exact 95% CI: 65.3%, 80.2%) relative to physician prescribed treatment, compared to a physician prescribed treatment response rate of 37.7% (95% CI: 30.0%, 46.1%). In the study, Cellworks Singula™ exhibited 90.9% sensitivity (95% CI: 80.0%, 97.0%) and 62.6% specificity (95% CI: 51.8%, 72.6%). In multivariate regression analysis, Singula™ (p < 0.0001) remained an independent predictor for CR after adjusting for patient age (p = 0.0759) and PPT (p = 0.0496).“We are committed to advancing Personalized Medicine,” said Yatin Mundkur, CEO of Cellworks. “Oncologists seek the ability to consistently prescribe cancer treatments with a high level of confidence that the chosen therapy will produce a response for an individual patient. Cellworks multi-omics biosimulation makes it possible to accurately predict whether a patient will respond to specific therapies. This Personalized Medicine knowledge can improve patient outcomes, reduce payer costs and ultimately save lives.”About Cellworks GroupCellworks Group, Inc. is a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology. Using innovative multi-omics modeling, computational biosimulation and Artificial Intelligence heuristics, Cellworks predicts the most efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. Backed by Sequoia Capital and Artiman Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal – attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California and has a research and development facility in Bangalore, India. For more information, visit www.cellworks.life and follow us on Twitter @cellworkslife.All trademarks and registered trademarks in this document are the properties of their respective owners.Media Contacts:Barbara Reichert
Reichert Communications, LLC
[email protected]
415-225-2991Michele Macpherson, Chief Business Officer
Cellworks Group, Inc.
[email protected]
Artificial Intelligence
Digital China’s Guo Wei Shares ‘China’s Sample’ of Global Digital Innovation with London Business School
LONDON, May 22, 2024 /PRNewswire/ — On May 21st, at the invitation of London Business School (LBS), Guo Wei, Chairman of Digital China, participated in the esteemed “Managing the Digital Organization” lecture, engaging with a cohort of prospective business leaders. Focusing on the trending topics of ‘Artificial Intelligence’ and ‘Digital Transformation’, he imparted the digital philosophy and practices of Chinese enterprises amidst the digital civilization era.
Digital China, a prominent player in China’s digital economy, has harnessed over two decades of deep involvement in the nation’s information industry to embrace the power of digitization. This has culminated in what Guo Wei refers to as ‘China’s Vibrant Blueprint for Digital Transformation’, carving a distinctive path of digital metamorphosis. Notably, Digital China’s transformation narrative has been incorporated into LBS’s esteemed case library, underscoring its significance as a teaching instrument.
In his lecture, Guo Wei emphasized that the digital economy now constitutes the backbone of supply, with digital technology emerging as the paramount catalyst for economic expansion. The hastening pace of global digitization propels us into an epoch of digital civilization. For multinational corporations, digital strategies have escalated to the status of corporate strategy, and the amassing of data assets constitutes the pivotal lever for business innovation. Amidst this evolution, AI-fueled digital-cloud integration signifies a disruptive technological innovation, poised to invigorate the global landscape. Digital China feels honored to reprise its role in elite international business school case repositories, thereby contributing insights to academia. This recognition signifies that Chinese enterprises’ digital and AI acumen resonates globally, exemplifying world-class practices.
Professor Julian Birkinshaw, Vice Dean and Professor of Strategy and Entrepreneurship at LBS, remarked, “As a global institution, we constantly seek out exemplary cases worldwide. Digital China was chosen not solely due to its prominence in China but also its sophisticated implementation of digital technologies, demonstrating adaptability and offering invaluable insights to our students about the contemporary business milieu. The story of Digital China encapsulates Mr. Guo Wei’s philosophy – digitization transcends being a mere process; it embodies the existential rationale for companies. This philosophy underpins our decision to feature Digital China in our case studies.”
Photo – https://mma.prnewswire.com/media/2419014/Digital_China_s_Guo_Wei_Professor_Julian_Birkinshaw.jpg
View original content:https://www.prnewswire.co.uk/news-releases/digital-chinas-guo-wei-shares-chinas-sample-of-global-digital-innovation-with-london-business-school-302152277.html
Artificial Intelligence
Saviynt Appoints James Ross as RVP-ANZ to Strategically Accelerate Growth in the Australia and New Zealand Region
LOS ANGELES, May 22, 2024 /PRNewswire/ — Saviynt, a leading provider of cloud-native identity and governance platform solutions, today announced the appointment of James Ross as RVP-ANZ as the company has seen rapid growth in the Australia and New Zealand (ANZ) region, with double digit growth year over year.
Saviynt has solidified its position as a key player in the cloud identity security landscape with its Identity Cloud. The company’s continued focus on innovation and client satisfaction has contributed significantly to building a safer Australia with prominent customers across the energy and utilities, finance, retail, energy, and transport and logistics sectors.
“James’ appointment as the Regional Vice President (RVP) for ANZ marks a strategic move to accelerate growth and solidify market presence in the region,” said Dan Mountstephen, SVP APAC at Saviynt. “With a proven track record of dynamic leadership at Collibra, ForgeRock, and CA Technologies, James brings a wealth of experience and expertise to the role. His visionary approach and collaborative spirit are poised to inspire and mobilize teams toward ambitious targets.”
Saviynt has consistently expanded its client base and deepened its relationships with existing customers through customized solutions and unparalleled support, cementing its reputation as a trusted partner in the region’s cybersecurity ecosystem. As RVP ANZ, Ross is set to foster key partnerships and implement agile strategies to propel the company towards new heights of success in the dynamic ANZ market.
“Joining Saviynt excites me because it’s an opportunity to help more organizations simplify their identity ecosystem in order to drive efficiencies and improved security posture. I am committed to leveraging Saviynt’s cutting-edge solutions to continue to broaden our partnerships in the region to improve our accessibility for customers, strengthen our regional delivery, whilst continuing to provide a great customer experience,” said Ross.
To learn more about Saviynt, please visit our website.
About Saviynt
Saviynt empowers enterprises to secure their digital transformation, safeguard critical assets, and meet regulatory compliance. With a vision to provide a secure and compliant future for all enterprises, Saviynt’s cutting-edge solutions have been recognized as industry leaders. For more information, please visit www.saviynt.com.
Press Contact
Jacklyn [email protected]
Photo: https://mma.prnewswire.com/media/2418209/James_Ross_RVP_ANZ_Saviynt.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/saviynt-appoints-james-ross-as-rvp-anz-to-strategically-accelerate-growth-in-the-australia-and-new-zealand-region-302151644.html
Unified Mobile Defense Platform Recognized for Innovation and Leadership Across Nine Cybersecurity Categories
REDWOOD CITY, Calif., May 21, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile defense, today announced it has received a total of nine (9) Cybersecurity Excellence Awards. The Appdome Unified Mobile App Defense Platform was awarded best in class across nine categories in recognition of the comprehensive breadth, depth and value of the Appdome platform to brands and enterprises alike.
“We congratulate Appdome on being recognized as an award winner in 9 categories of the 2024 Cybersecurity Excellence Awards,” said Holger Schulze, CEO of Cybersecurity Insiders and founder of the 600,000-member Information Security Community on LinkedIn, which organizes the 9th annual Cybersecurity Excellence Awards. “With over 600 entries across more than 300 categories, the awards are highly competitive. Appdome’s achievement reflects outstanding commitment to the core principles of excellence, innovation, and leadership in cybersecurity.”
Within a single pane of glass, Appdome delivers the most complete set of no-code, no-SDK, fully automated mobile defenses to mobile brands and enterprises, empowering mobile developers, cybersecurity, fraud and IT teams to deliver on any mobile cyber objective quickly and easily.
The nine (9) categories in which Appdome received a Cybersecurity Excellence Award are:
Mobile Security Platform: Appdome is the only enterprise-grade mobile security platform built for full mobile defense lifecycle management, visibility and control to brands and enterprises alike, including key features for build, test, release, monitor, response, and compliance automation. Mobile Security Automation: Appdome is the only mobile defense solution that uses machine learning to code and build over 300+ mobile app security, anti-fraud, anti-cheat, anti-malware, anti-bot, geo-compliance and other defenses in Android & iOS apps in the DevOps pipeline.Mobile Social Engineering Defense: The Appdome Social Engineering Prevention solution is the first of its kind to protect mobile users from voice phishing (Vishing) scams and other imposter scams, T.O.A.D. attacks, Remote Access Trojans (RATs), Gold Pickaxe, FaceID bypass and more without an SDK or external servers.Mobile Bot Defense: The Appdome MOBILEBot™ Defense solution is the first mobile anti-bot solution to come out of the box compatible with any industry standard web application firewall (WAF) on the market and provide multi-layered bot, credential stuffing and Account Take Over (ATO) defense without an SDK, external server, performance limits, or restrictions.Mobile Geo Compliance: Only the Appdome Mobile Geo-Compliance solution guarantees accurate and authentic geo location of mobile devices, applications and users without code or coding in the mobile app, without implementing an SDK and without deploying additional servers.Mobile XDR: The Appdome ThreatScope™ Mobile XDR solution is the only mobile attack and threat monitoring service that comes pre-packaged into the mobile defense lifecycle, requires no device agent, device profile, separate code, coding, SDK or server, and provides real-time detection and automated response across internal (employee facing) and external (consumer facing) Android & iOS apps.DevOps Mobile Security Tool: The Appdome platform’s fully integrated Security Release Management™ capabilities and Appdome Certified Secure™ mobile DevSecOps certification offer the only true enterprise-grade compliance assurance, audit and control for mobile defense at brands and enterprises, allowing quick verification that all security, anti-fraud and compliance objectives have been met. Mobile Application Security: With 300+ separate defenses for mobile apps, Appdome has the most comprehensive set of mobile application security features available in one product, fully compatible with all mobile Android & iOS apps.”Nine Cybersecurity Excellence Awards for Mobile Defense tells a very compelling story for the incredibly complex Dev, Sec, and Ops challenges organizations face detecting and defeating mobile-based risks and attacks,” said Chris Roeckl, Chief Product Officer at Appdome. “Point products make these challenges worse by adding complexity and overloading already taxed cyber and engineering teams. Appdome is the only platform simplifying work, bringing all these unique challenges under a single pane of glass, delivering 300+ protections and simultaneously resolving the security, fraud, resilience and compliance challenges brands and enterprises face.”
Learn more about the award-winning Appdome Platform at www.appdome.com or request a personalized demo at https://www.appdome.com/request-a-demo/appdome-home/
The full list of awards are available from the Cybersecurity Excellence Awards website https://cybersecurity-excellence-awards.com/
About AppdomeThe Appdome mission is to protect every mobile app and mobile user in the world. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control, and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
Logo – https://mma.prnewswire.com/media/772169/AppDome_Logo_9_27_23.jpg
View original content:https://www.prnewswire.co.uk/news-releases/appdome-sweeps-cybersecurity-excellence-awards-302151786.html
-
Artificial Intelligence6 days agoJapan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized4 days agoCoca-Cola: The future is ‘AI meets human ingenuity’
-
Uncategorized6 days ago
Google to roll out AI-generated summaries at top of search engine
-
Artificial Intelligence5 days agoStrava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence4 days agoMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days agoData Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence6 days ago
IBM Expands Qiskit, World’s Most Performant Quantum Software
-
Artificial Intelligence6 days ago
IoT Sensors Market to be Worth $71.6 Billion by 2031- Exclusive Report by Meticulous Research®
